Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DIATREME RESOURCES LIMITED M&A Activity 2024

Feb 25, 2024

64787_rns_2024-02-25_f7aed8d8-c0bc-49b3-99da-b125dadad72f.pdf

M&A Activity

Open in viewer

Opens in your device viewer

==> picture [338 x 122] intentionally omitted <==

==> picture [195 x 67] intentionally omitted <==

ASX ANNOUNCEMENT

26 February 2024

Update on preliminary conditions to intention to make takeover bid for Metallica Minerals Limited

Diatreme Resources Limited (ASX: DRX) ( Diatreme ) refers to its announcement on 16 February 2024 in relation to its conditional intention to make a takeover bid for all of the ordinary shares in Metallica Minerals Limited (ASX: MLM) ( Metallica ), under which Metallica shareholders would receive 1.3319 ordinary shares in Diatreme ( Diatreme Shares ) for each ordinary share in Metallica ( Metallica Share ) held by Metallica shareholders on the record date ( Offer ). As outlined in the 16 February 2024 announcement, Diatreme’s intention to make the Offer is subject to satisfaction of certain preliminary conditions.

Satisfaction of first preliminary condition

Diatreme has received confirmation from ASIC that a modification to section 629 of the Corporations Act 2001 (Cth) ( Corporations Act ) is not required in order to include as a defeating condition to the Offer, a condition requiring the approval of Diatreme shareholders for the purpose of Listing Rule 10.1 for the acquisition of the Metallica Shares held by Ilwella Pty Ltd ( Ilwella ) and Sibelco Asia Pacific Pty Ltd ( Sibelco ) (and the issue of Diatreme Shares for each Metallica Share held by Ilwella and Sibelco, to Ilwella and Sibelco as consideration under the Offer) ( Listing Rule 10.1 Approval ).

Based on this confirmation, Diatreme intends to withdraw its application with ASIC. Diatreme hereby confirms that the preliminary condition to the Offer in respect of the modification to section 629 of the Corporations Act has been satisfied.

Update on outstanding preliminary condition

Diatreme is yet to receive a decision on its ASX waiver application and as such, the condition regarding modification of section 625(3) of the Corporations Act remains as set out in the 16 February 2024 announcement. Diatreme will provide a further update to the market on the status of this preliminary condition following the outcome of the ASX application.

This market announcement was authorised for release by:

Neil McIntyre Chief Executive Officer

Greg Starr Non-executive Director

Page 1 of 2

==> picture [338 x 122] intentionally omitted <==

==> picture [195 x 67] intentionally omitted <==

Contact – Mr Neil McIntyre - Ph – +61 (0)7 3397 2222 Website - www.diatreme.com.au Email - [email protected]

For investor/media queries, please contact: Anthony Fensom, Fensom Advisory [email protected] Ph: +61 (0)407 112 623

For more information, please visit www.diatreme.com.au

Page 2 of 2